Company intelligence / Profile preview

Amsterdam Molecular Therapeutics

Amsterdam, Netherlandsamtbv.com ↗

Ownership: Private
Development stage: Other

Overview

The company developed Glybera, the first approved gene therapy in the Western world. The assets of AMT were acquired by uniQure BV. As uniQure, the company has received FDA approval for hemophilia B gene therapy in 2022.

Therapeutic areas: HematologyRare DiseasesNeurologyMetabolic Disorders
Modalities: Gene therapyAAV vectors
Industry: Biotech

Beyond the preview

Go deeper on Amsterdam Molecular Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Amsterdam Molecular Therapeutics.